Blueprint in hand, NIH embarks on study of a million people
By Jocelyn Kaiser,
Science Insider
| 09. 17. 2015
Untitled Document
Hoping to avoid the potholes that recently wrecked a similarly ambitious study of children, a panel of human geneticists, medical researchers, and other experts today proposed a blueprint for the National Institutes of Health's (NIH's) plan to recruit 1 million Americans for a long-term study of genes and health. The study, which hopes to recruit its first volunteers next year and could last a decade or longer, may become the largest national study of this kind in the world.
For NIH Director Francis Collins, the project, known as the Precision Medicine Initiative (PMI) Cohort Program, brings to fruition an idea he first proposed 11 years ago. “I am so excited to see this dream come to life,” Collins said in a statement released after he accepted the blueprint. “[It] will be a broad, powerful resource for researchers working on a variety of important health questions.”
President Obama called for a large national research study in January as part of a broader effort to use genetics and health information to tailor medical care to individuals. Several countries, including the...
Related Articles
By Anna Louie Sussman, The New York Times | 07.01.2026
Birthrates in much of the developed world are at record lows, but there’s one demographic group that’s exploring new frontiers of fertility: ultrawealthy men. Deploying nearly limitless resources, a small number of them are reproducing at such an extraordinary scale...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Anna Rogers, Mother Jones | 06.19.2026
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...